July 22, 2025 a 07:43 am

PODD: Fundamental Ratio Analysis - Insulet Corporation

Insulet Corporation Stock Analysis

Insulet Corporation, under the ticker PODD, shows potential in the medical devices sector, focusing on innovative insulin delivery systems. The stock’s fundamentals reveal a balanced perspective, with room for growth in certain areas such as the discounted cash flow. Investors should consider both current and historical ratings alongside analyst sentiments for a comprehensive evaluation.

Fundamental Rating

The current fundamentals suggest a moderate evaluation with strong points in return ratios, but challenges remain in valuation metrics.

Category Score Visualization
Discounted Cash Flow (DCF) 1
Return on Equity (ROE) 5
Return on Assets (ROA) 5
Debt to Equity 3
Price to Earnings 1
Price to Book 1

Historical Rating

Comparison of current vs. past scores highlights consistent performance in key areas such as ROE and ROA.

Date Overall Score DCF ROE ROA Debt/Equity P/E P/B
2025-07-21 3 1 5 5 3 1 1
N/A 0 1 5 5 3 1 1

Analyst Price Targets

Analyst targets provide a consistent outlook with the current consensus aligning with the median price target.

High Low Median Consensus
$322 $322 $322 $322
Stock chart of Insulet Corporation

Analyst Sentiment

The analyst sentiment reflects a generally positive outlook, with a majority of analysts recommending a 'Buy'.

Recommendation Count Visualization
Strong Buy 0
Buy 28
Hold 13
Sell 2
Strong Sell 0

Conclusion

Insulet Corporation presents a strong case in the healthcare market, with innovative solutions in the insulin delivery segment. While the company shows promising returns on equity and assets, valuation metrics remain an area for improvement. The analyst sentiment is predominantly positive, with a consensus towards buying, reflecting confidence in the company's future prospects. However, potential investors should consider market dynamics and financial strategies for debt management. Overall, the stock holds potential for long-term growth, especially with advancements in its product offerings.